By modulating metastatic pathways such as TGF-β, NF-κB, and PI3K/AKT/mTOR signaling, which are involved in tumor progression and metastasis, these combination strategies have the potential to improve clinical outcomes and provide durable responses for OC patients with fewer adverse effects. This evidence concerns the gene AKT1 and neoplasm.